Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Finished Goods (2017 - 2019)

Ironwood Pharmaceuticals' Finished Goods history spans 3 years, with the latest figure at $191000.0 for Q4 2019.

  • For Q4 2019, Finished Goods changed N/A year-over-year to $191000.0; the TTM value through Dec 2019 reached $191000.0, changed N/A, while the annual FY2019 figure was $191000.0, N/A changed from the prior year.
  • Finished Goods for Q4 2019 was $191000.0 at Ironwood Pharmaceuticals, down from $457000.0 in the prior quarter.
  • Across five years, Finished Goods topped out at $1.4 million in Q1 2018 and bottomed at $76000.0 in Q3 2018.
  • The 3-year median for Finished Goods is $479000.0 (2017), against an average of $589428.6.
  • The largest annual shift saw Finished Goods tumbled 84.13% in 2018 before it skyrocketed 501.32% in 2019.
  • A 3-year view of Finished Goods shows it stood at $735000.0 in 2017, then tumbled by 89.66% to $76000.0 in 2018, then surged by 151.32% to $191000.0 in 2019.
  • Per Business Quant, the three most recent readings for IRWD's Finished Goods are $191000.0 (Q4 2019), $457000.0 (Q3 2019), and $76000.0 (Q3 2018).